Insider Selling: GenMark Diagnostics SVP Sells 6,000 Shares of Stock (GNMK)
GenMark Diagnostics (NASDAQ:GNMK) SVP Jon Faiz Kayyem sold 6,000 shares of GenMark Diagnostics stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $12.14, for a total transaction of $72,840.00. Following the transaction, the senior vice president now directly owns 106,806 shares in the company, valued at approximately $1,296,625. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of GenMark Diagnostics (NASDAQ:GNMK) traded up 2.62% during mid-day trading on Friday, hitting $12.52. The stock had a trading volume of 262,377 shares. GenMark Diagnostics has a one year low of $7.55 and a one year high of $16.00. The stock has a 50-day moving average of $11.57 and a 200-day moving average of $12.24. The company’s market cap is $409.8 million.
GenMark Diagnostics (NASDAQ:GNMK) last announced its earnings results on Wednesday, August 7th. The company reported ($0.25) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.26) by $0.01. The company had revenue of $5.20 million for the quarter, compared to the consensus estimate of $5.05 million.
A number of analysts have recently weighed in on GNMK shares. Analysts at Raymond James raised their price target on shares of GenMark Diagnostics (NASDAQ:GNMK) to $15.00 in a research note to investors on Wednesday. Finally, analysts at Canaccord Genuity cut their price target on shares of GenMark Diagnostics (NASDAQ:GNMK) from $18.00 to $14.00 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating and three have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $14.67.
GenMark Diagnostics, Inc (NASDAQ:GNMK) is a molecular diagnostics company focused on developing and commercializing its eSensor detection technology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.